INT12602

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.59
First Reported 1987
Last Reported 2010
Negated 5
Speculated 8
Reported most in Abstract
Documents 190
Total Number 198
Disease Relevance 36.11
Pain Relevance 177.85

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

signal transduction (Oprm1) plasma membrane (Oprm1) signal transducer activity (Oprm1)
Anatomy Link Frequency
brain 9
neurons 6
spinal cords 4
neuronal 4
spinal 2
Oprm1 (Mus musculus)
Oprm1 - T180A (1)
Pain Link Frequency Relevance Heat
opioid receptor 2168 100.00 Very High Very High Very High
Morphine 1750 100.00 Very High Very High Very High
mu opioid receptor 1222 100.00 Very High Very High Very High
Opioid 775 100.00 Very High Very High Very High
agonist 445 100.00 Very High Very High Very High
narcan 258 100.00 Very High Very High Very High
antagonist 200 100.00 Very High Very High Very High
antinociception 178 100.00 Very High Very High Very High
Fibrositis 21 100.00 Very High Very High Very High
Cholecystokinin 17 100.00 Very High Very High Very High
Disease Link Frequency Relevance Heat
Targeted Disruption 157 100.00 Very High Very High Very High
Repression 102 100.00 Very High Very High Very High
Contagious Ecthyma 56 100.00 Very High Very High Very High
Neuroblastoma 20 100.00 Very High Very High Very High
Hyperalgesia 17 99.92 Very High Very High Very High
Diabetes Mellitus 10 99.88 Very High Very High Very High
Urological Neuroanatomy 234 99.68 Very High Very High Very High
Fibromyalgia 16 99.64 Very High Very High Very High
Attention Deficit Hyperactivity Disorder 61 99.60 Very High Very High Very High
INFLAMMATION 88 99.58 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Etorphine produced dose-dependent downregulation of mu-opioid receptor density and tolerance (ED(50) shift at highest infusion dose, 6.97).
Negative_regulation (downregulation) of mu-opioid receptor associated with tolerance, opioid receptor and immobilon
1) Confidence 0.59 Published 2001 Journal Pharmacol. Biochem. Behav. Section Abstract Doc Link 11420091 Disease Relevance 0 Pain Relevance 1.76
Continuous opioid agonist treatment produces tolerance and in some cases mu opioid receptor (muOR) down-regulation.
Negative_regulation (down-regulation) of muOR associated with mu agonist, mu opioid receptor and tolerance
2) Confidence 0.58 Published 2005 Journal Synapse Section Abstract Doc Link 15765525 Disease Relevance 0 Pain Relevance 0.71
It has been suggested that muOR down-regulation may depend upon increases in Dynamin-2 (DYN-2) proteins.
Negative_regulation (down-regulation) of muOR
3) Confidence 0.58 Published 2005 Journal Synapse Section Abstract Doc Link 15765525 Disease Relevance 0 Pain Relevance 0.80
Continuous opioid agonist treatment produces tolerance and in some cases mu opioid receptor (muOR) down-regulation.
Negative_regulation (down-regulation) of mu opioid receptor associated with mu agonist, mu opioid receptor and tolerance
4) Confidence 0.58 Published 2005 Journal Synapse Section Abstract Doc Link 15765525 Disease Relevance 0 Pain Relevance 0.71
Mice lacking the mu receptor showed normal fear acquisition when subjected to a 1-day fear conditioning protocol but evinced deficient fear learning when acquisition was conducted across 5 days.
Negative_regulation (lacking) of mu receptor associated with anxiety disorder
5) Confidence 0.58 Published 2005 Journal Neurobiol Learn Mem Section Abstract Doc Link 15936681 Disease Relevance 1.08 Pain Relevance 0.38
These results indicate that desensitization of the mu receptor may be a molecular basis for the development of tolerance to fentanyl and its analogs.
Negative_regulation (desensitization) of mu receptor associated with tolerance
6) Confidence 0.58 Published 1998 Journal J. Pharmacol. Exp. Ther. Section Abstract Doc Link 9618424 Disease Relevance 0 Pain Relevance 0.40
However, this plasma glucose lowering response to cold-stress was disappeared in diabetic mice lacking opioid mu-receptor.
Negative_regulation (lacking) of mu-receptor in plasma associated with stress, diabetes mellitus and opioid
7) Confidence 0.58 Published 2001 Journal Neurosci. Lett. Section Abstract Doc Link 11427305 Disease Relevance 1.11 Pain Relevance 0.74
These effects on ethanol reward were produced by reductions in MOR expression levels as small as 50%.
Negative_regulation (reductions) of MOR
8) Confidence 0.58 Published 2001 Journal Psychopharmacology (Berl.) Section Body Doc Link 11292005 Disease Relevance 0 Pain Relevance 0
However, PTX had no effect on etorphine-induced mu-opioid receptor down-regulation in brain, cord, or midbrain.
Negative_regulation (down-regulation) of mu-opioid receptor in brain associated with midbrain, opioid receptor and immobilon
9) Confidence 0.58 Published 2002 Journal Pharmacol. Biochem. Behav. Section Abstract Doc Link 11900797 Disease Relevance 0.05 Pain Relevance 1.64
Mu-opioid receptor down-regulation and tolerance are not equally dependent upon G-protein signaling.
Negative_regulation (down-regulation) of Mu-opioid receptor associated with tolerance and opioid receptor
10) Confidence 0.58 Published 2002 Journal Pharmacol. Biochem. Behav. Section Title Doc Link 11900797 Disease Relevance 0.10 Pain Relevance 1.06
Morphine treatment also produced significant tolerance (ED50 shift= approximately 5-8-fold), but no mu-opioid receptor down-regulation.
Negative_regulation (down-regulation) of mu-opioid receptor associated with tolerance, opioid receptor and morphine
11) Confidence 0.58 Published 2002 Journal Pharmacol. Biochem. Behav. Section Abstract Doc Link 11900797 Disease Relevance 0.06 Pain Relevance 1.64
Etorphine produced dose-dependent tolerance as well as down-regulation of mu receptor density.
Negative_regulation (down-regulation) of mu receptor associated with tolerance and immobilon
12) Confidence 0.58 Published 1993 Journal J. Pharmacol. Exp. Ther. Section Abstract Doc Link 8386239 Disease Relevance 0 Pain Relevance 1.07
Morphine treatment produced significant tolerance (ED(50) shift approximately 9-fold), but no mu-opioid receptor downregulation.
Neg (no) Negative_regulation (downregulation) of mu-opioid receptor associated with tolerance, opioid receptor and morphine
13) Confidence 0.58 Published 2003 Journal Synapse Section Abstract Doc Link 12454948 Disease Relevance 0 Pain Relevance 1.64
Compared to wild type mice, a response in the dopaminergic behavior by treatment with delta-receptor agonist, DPDPE, is more sensitive to the mice lacking mu-opioid receptor.
Negative_regulation (lacking) of mu-opioid receptor associated with agonist and opioid receptor
14) Confidence 0.58 Published 2001 Journal Brain Res. Mol. Brain Res. Section Abstract Doc Link 11597780 Disease Relevance 0.25 Pain Relevance 0.67
The differences among 3 drugs are as follows: 1) The in vitro incubation with Mor, but not with Pent and EtOH developed tolerance. 2) MVD from Mor and EtOH tolerant animals were also tolerant to the inhibitory effect of Mor and EtOH in vitro, respectively. 3) K+ and Ca2+ stimulated the contractions of MVD and the effect was enhanced further after incubation in Mor. 4) The administration of Mor and Pent dose-dependently enhanced the effect of K+ and Ca2+, but this effect of Mor was lost following repeated injections. 5) No cross tolerance was developed among 3 drugs in the inhibitor effect following in vitro incubation or in vivo treatment.
Negative_regulation (effect) of Mor in MVD associated with tolerance and morphine
15) Confidence 0.58 Published 1989 Journal J. Pharmacobio-dyn. Section Abstract Doc Link 2614644 Disease Relevance 0 Pain Relevance 0.95
Results of radioligand binding and transfected receptor studies indicate that mu-receptor down-regulation and phosphorylation may be critical to the expression of morphine tolerance.
Negative_regulation (regulation) of mu-receptor associated with tolerance and morphine
16) Confidence 0.57 Published 1998 Journal Brain Res. Mol. Brain Res. Section Abstract Doc Link 9582426 Disease Relevance 0 Pain Relevance 0.79
These results suggest that down-regulation of MOR in the distinct populations of DRG neurons contributes to the fact that higher doses of morphine are needed to produce analgesia in bone cancer as compared with those used in non-malignant inflammatory situations.
Negative_regulation (down-regulation) of MOR in DRG associated with dorsal root ganglion, malignant neoplastic disease, inflammation, opioid receptor, bone cancer, analgesia and morphine
17) Confidence 0.57 Published 2008 Journal Neuroscience Section Abstract Doc Link 18178319 Disease Relevance 1.60 Pain Relevance 1.33
Synthesis and biological evaluation of 14-alkoxymorphinans, V: 6-Deoxyocyprodime, an opioid antagonist with decreased mu receptor selectivity in comparison to cyprodime.
Negative_regulation (decreased) of mu receptor associated with antagonist and opioid
18) Confidence 0.56 Published 1991 Journal Arch. Pharm. (Weinheim) Section Title Doc Link 1650547 Disease Relevance 0 Pain Relevance 0.19
Mu-opioid receptor up-regulation has been associated with decreases in the trafficking protein dynamin-2, whereas mu-opioid receptor down-regulation produces an increase in dynamin-2 abundance.
Negative_regulation (down-regulation) of mu-opioid receptor associated with opioid receptor
19) Confidence 0.56 Published 2004 Journal Eur. J. Pharmacol. Section Abstract Doc Link 15363980 Disease Relevance 0 Pain Relevance 1.22
Continuous (7 days) s.c. infusion of etorphine (200 microg/kg/day) decreased immunoreactive mu-opioid receptor (approximately -35%) and [3H] DAMGO binding (approximately -30%), and concurrently increased dynamin-2 abundance (approximately +40%).
Negative_regulation (decreased) of mu-opioid receptor associated with opioid receptor and immobilon
20) Confidence 0.56 Published 2004 Journal Eur. J. Pharmacol. Section Abstract Doc Link 15363980 Disease Relevance 0 Pain Relevance 1.19

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox